Shah Capital Management
- SEC CIK
- 0001383838
- Latest filing
- Aug 14, 2026
The latest 13F from Shah Capital Management covers Q2 2026 (filed Aug 14, 2026): 9 long positions worth $526.2M. The top 10 holdings make up 100.0% of the portfolio, and the largest is VEON Ltd. (VEON) at 46.3%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 1
- Est. +$2.29M
- Reduced
- 8
- Est. −$35.8M
- Sold out
- 2
- Est. −$11.8M
Top 5 holdings
Share of this quarter's portfolio value
Biggest buys
New and added positions, by estimated amount bought
- Vanguard Scottsdale FDS92206C102+$2.29MAdded
Largest weight increases
New and added positions, by percentage points of the portfolio gained
- Vanguard Scottsdale FDS92206C102+0.38 pp3.9% → 4.2%
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $526.2M
- +$4.99M (+1.0%) vs. prior quarter
- Positions
- 9
- −2 vs. prior quarter
- Top 10 concentration
- 100.0%
- Top 10 as share of value
- Turnover
- 0.4%
- Q2 2026, one quarter
- Average holding period
- 13.6 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $559.0M (Q3 2025)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 9 | $526.2M | VEONNVAXCYD | vs. Q1 2026 | SEC |
| Q1 2026 | Apr 24, 2026 | 11 | $521.2M | VEONNVAXCYD | vs. Q4 2025 | SEC |
| Q4 2025 | Jan 15, 2026 | 12 | $518.5M | VEONNVAXCYD | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 12, 2025 | 13 | $559.0M | VEONNVAXCYD | vs. Q2 2025 | SEC |
| Q2 2025 | Jul 23, 2025 | 14 | $514.0M | VEONCYDNVAX | vs. Q1 2025 | SEC |
| Q1 2025 | May 14, 2025 | 17 | $489.6M | VEONNVAXCYD | vs. Q4 2024 | SEC |
| Q4 2024 | Jan 22, 2025 | 16 | $495.9M | VEONNVAXCYD | vs. Q3 2024 | SEC |
| Q3 2024 | Oct 15, 2024 | 19 | $513.0M | VEONNVAXCYD | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 12, 2024 | 17 | $462.3M | VEONNVAXCYD | vs. Q1 2024 | SEC |
| Q1 2024 | May 15, 2024 | 17 | $357.4M | VEONEDUNVAX | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 5, 2024 | 15 | $390.4M | VEONEDUSOL | vs. Q3 2023 | SEC |
| Q3 2023 | Oct 11, 2023 | 14 | $422.7M | EDUVEONRenesola Ltd-Spon | vs. Q2 2023 | SEC |
| Q2 2023 | Jul 13, 2023Amended | 15 | $393.5M | EDUVEONRenesola Ltd-Spon | vs. Q1 2023 | SEC |
| Q1 2023 | May 8, 2023 | 16 | $343.7M | EDUVEONRenesola Ltd-Spon | vs. Q4 2022 | SEC |
| Q4 2022 | Jan 13, 2023 | 15 | $420.9M | EDURenesola Ltd-SponGNW | vs. Q3 2022 | SEC |
| Q3 2022 | Oct 27, 2022 | 12 | $349.9M | Renesola Ltd-SponEDUAR | vs. Q2 2022 | SEC |
| Q2 2022 | Jul 25, 2022 | 13 | $385.7M | EDURenesola Ltd-SponVanguard Scottsdale FDS | vs. Q1 2022 | SEC |
| Q1 2022 | Apr 19, 2022 | 12 | $386.9M | ARRenesola Ltd-SponGNW | vs. Q4 2021 | SEC |
| Q4 2021 | Jan 19, 2022 | 10 | $374.9M | ARRenesola Ltd-SponCYD | vs. Q3 2021 | SEC |
| Q3 2021 | Oct 8, 2021 | 9 | $369.7M | ARRenesola Ltd-SponCYD | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 10, 2021 | 8 | $353.9M | Renesola Ltd-SponARCYD | vs. Q1 2021 | SEC |
| Q1 2021 | May 4, 2021 | 7 | $362.9M | Renesola Ltd-SponARCYD | – | SEC |
13D and 13G filings
Companies where Shah Capital Management reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
1 company, largest stake first.
Latest filings
35 filings on file made by Shah Capital Management or listing it as a reporting person; the latest 20 are shown.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| NVAXNovavax Inc | May 15, 20268:15 AM ET | 13D/A | 9.03%14.8M shares | −0.08 ppfrom 9.11% | May 14, 2026 | SEC |
| NVAXNovavax Inc | Apr 8, 20266:00 AM ET | 13D/A | 9.11%14.8M shares | +0.81 ppfrom 8.30% | Apr 8, 2026 | SEC |
| SOLEmeren Group Ltd | Dec 16, 20258:47 AM ET | 13D/A | 0.00%0 shares | −36.67 ppfrom 36.67%Below 5% | Dec 12, 2025 | SEC |
| NVAXNovavax Inc | Nov 12, 20254:17 PM ET | 13D/A | 8.30%13.5M shares | +1.00 ppfrom 7.30% | Nov 10, 2025 | SEC |
| CYDChina Yuchai International Ltd | Nov 12, 20258:51 AM ET | 13G/A | 4.46%1.67M shares | −4.40 ppfrom 8.86%Below 5% | Sep 30, 2025 | SEC |
| NVAXNovavax Inc | Oct 14, 20257:45 AM ET | 13D/A | 7.30%11.8M shares | – | Oct 13, 2025 | SEC |
| CHRCheer Holding, Inc. | Oct 7, 20254:13 PM ET | 13G/A | 2.47%600.0K shares | −15.66 ppfrom 18.13%Below 5% | Oct 3, 2025 | SEC |
| SOLEmeren Group Ltd | Sep 3, 20254:53 PM ET | 13D/A | 36.67%18.8M shares | 0.00 ppfrom 36.67% | Sep 2, 2025 | SEC |
| CHRCheer Holding, Inc. | Aug 6, 20253:09 PM ET | 13G/A | 18.13%2.11M shares | +3.48 ppfrom 14.65% | Jun 30, 2025 | SEC |
| SOLEmeren Group Ltd | Jul 7, 20255:08 PM ET | 13D/A | 36.67%18.8M shares | 0.00 ppfrom 36.67% | Jul 3, 2025 | SEC |
| SOLEmeren Group Ltd | Jun 20, 202510:37 AM ET | 13D/A | 36.67%18.8M shares | −0.01 ppfrom 36.68% | Jun 20, 2025 | SEC |
| CYDChina Yuchai International Ltd | May 6, 20255:20 PM ET | 13G/A | 8.86%3.32M shares | – | Mar 31, 2025 | SEC |
| CHRCheer Holding, Inc. | May 6, 202510:56 AM ET | 13G/A | 14.65%1.71M shares | −1.05 ppfrom 15.70% | Mar 31, 2025 | SEC |
| SOLEmeren Group Ltd | Mar 17, 202511:38 AM ET | 13D/A | 36.68%18.8M shares | – | Mar 17, 2025 | SEC |
| CHRCheer Holding, Inc. | Jan 8, 20251:08 PM ET | 13G/A | 15.70%1.61M shares | – | Dec 31, 2024 | SEC |
| VEONVEON Ltd. | Oct 21, 2024 | 13D/AOld format | – | – | – | SEC |
| CYDChina Yuchai International Ltd | Sep 3, 2024 | 13GOld format | – | – | – | SEC |
| CHRCheer Holding, Inc. | Jul 12, 2024 | 13G/AOld format | – | – | – | SEC |
| NVAXNovavax Inc | May 20, 2024 | 13D/AOld format | – | – | – | SEC |
| NVAXNovavax Inc | May 7, 2024 | 13D/AOld format | – | – | – | SEC |